Atlantic City

Researchers are evaluating an experimental treatment called intra-arterial delivery of verapamil in patients diagnosed with acute ischemic stroke. This study focuses on testing the safety of verapamil, a drug used to treat blood vessel spasms, and its effects on the recovery process after a stroke. The study is limited to patients who have already received mechanical thrombectomy as their standard care. This trial is conducted in Phase 1 and Phase 2 to better understand the treatment's safety and potential benefits. Participants will receive intra-arterial verapamil after their mechanical thrombectomy procedure. The verapamil will be given at one of two randomized doses: 10 mg or 20 mg. The treatment is delivered directly into the artery to target the affected area. This approach aims to reduce blood vessel spasms and improve neurological outcomes following a stroke. During the study, researchers will monitor participants for bleeding complications and any serious adverse events, including death, over a three-month period. Participants will also be expected to follow up with rehabilitation therapy as part of their recovery. The study includes careful safety monitoring and assessments to understand the effects of the treatment and ensure participant well-being throughout the trial period.